Ibrexafungerp - SCYNEXIS
Alternative Names: Brexafemme; GSK 5458448; Ibrexafungerp citrate; MK-3118; SCY 078; SCY-078-citrateLatest Information Update: 28 Apr 2024
At a glance
- Originator Merck & Co; SCYNEXIS
- Developer Jiangsu Hansoh Pharmaceutical; Merck & Co; SCYNEXIS
- Class Alkanes; Amines; Antifungals; Carboxylic acids; Ethers; Glycosides; Heterocyclic compounds; Pyridines; Small molecules; Triazoles; Triterpenes
- Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Vulvovaginal candidiasis
Highest Development Phases
- Marketed Vulvovaginal candidiasis
- Phase III Candidiasis; Invasive candidiasis
- Phase II Invasive bronchopulmonary aspergillosis
- Preclinical Mycoses
- No development reported Pneumocystis pneumonia; Unspecified
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Candidiasis(In volunteers) in South Africa (IV)
- 13 Nov 2023 Scynexis completes a phase III VANQUISH trial in Vulvovaginal candidiasis (In adults, In the elderly, Treatment-experienced) in USA (PO) (NCT05399641)
- 13 Nov 2023 The phase III MARIO trial for Candidiasis was placed on clinical hold due to this potential cross-contamination in Bulgaria, Spain, South Africa, Greece, Belgium, USA (PO) (NCT05178862)